Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.